Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,818 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06082050RecruitingEarly Phase 1
YOLT-201 for transthyretin heart disease
This trial tests a new intravenous medicine called YOLT-201 for people with a heart condition caused by buildup of a protein called transthyretin (ATTR-CM). The goal is to see if it can slow or improve the disease.
Hangzhou, ZhejiangAges 18–80 - NCT06065748RecruitingPhase 3
New hormone therapy for advanced breast cancer after prior treatment
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
Daphne, AlabamaAges 18 years+ - NCT07143773RecruitingPhase 4
SGLT2i safety in kidney transplant patients without diabetes
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
OdenseAges 18 years+ - NCT06766357RecruitingPhase 3
Cyclosporin gel for moderate to severe dry eye
This study tests a gel form of cyclosporine for people with moderate to severe dry eye that hasn't improved with other treatments. The gel is applied to the eye to help reduce inflammation and increase tear production.
Xiamen, FujianAges 18 years+ - NCT07159087Enrolling by invitation
New drug balloon for re-narrowed stents
This trial tests a new drug-coated balloon (Genoss SCB) versus an existing one (SeQuent Please NEO) for people whose heart stents have re-narrowed. It aims to see which balloon better keeps the artery open.
Gyeonggi-doAges 19 years+ - NCT06205862RecruitingPhase 2
Fecal transplant for preventing colon polyp return
This study tests whether taking capsules of healthy bacteria (fecal microbiota transplant) can help prevent colon polyps from coming back after they have been removed. It might be an option for people who have had an adenoma polyp removed and want to reduce the chance of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06462469RecruitingPhase 4
Ruxolitinib for steroid-resistant graft-versus-host disease
This trial tests a new pill, ruxolitinib, for people whose acute graft-versus-host disease (a complication after a stem cell transplant) is not improving with steroids. It aims to see if it can better control the disease and improve recovery.
Guangzhou, GuangdongAges 12–100 - NCT06529549Recruiting
Organoid drug test for advanced prostate cancer
This trial uses a lab test on a tiny sample of your tumor (called an organoid) to find which drug might work best for your advanced prostate cancer. It's for men whose cancer has stopped responding to hormone therapy and got worse after first treatment.
Guangzhou, GuangdongAges 18–75 - NCT07656753RecruitingEarly Phase 1
Gene therapy trial for RLBP1-related retinal dystrophy
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
Beijing, Beijing MunicipalityAges 18–55 - NCT06490484RecruitingPhase 2
A new capsule for diabetic nerve pain when pregabalin doesn't work
This trial tests an experimental drug (HSK16149) for people with long-term diabetic nerve pain that hasn't been helped enough by pregabalin. It aims to see if the new capsule can reduce pain more effectively.
Hangzhou, ZhejiangAges 18–75 - NCT07450040Enrolling by invitation
Tislelizumab plus chemo for early-stage NK/T-cell lymphoma
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
Shanghai, ChinaAges 18–70 - NCT04576143RecruitingPhase 2/Phase 3
Dose-dense chemo before surgery for HER2-negative breast cancer
This trial studies a faster, higher-frequency chemotherapy schedule given before surgery for HER2-negative breast cancer. It aims to see if this approach works better and is safe for the patient’s cancer stage.
Hangzhou, ZhejiangAges 18–70 - NCT07126912Recruiting
Alcarisa filler for mid-face volume restoration
This trial tests a new hyaluronic acid filler called Alcarisa to restore volume in the mid-face (cheek area). It may be a good option if you are looking for a non-surgical way to treat moderate to significant cheek volume loss.
Tehran, Tehran ProvinceAges 30–65 - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Phoenix, ArizonaAges 18 years+ - NCT06343298RecruitingPhase 2
Testing MANP for hard-to-control high blood pressure
This trial tests a new drug called MANP for people whose blood pressure stays high despite taking three or more different types of blood pressure medications. The goal is to see if MANP is safe and effective in lowering blood pressure.
Little Rock, ArkansasAges 18–80 - NCT05754450RecruitingPhase 3
Extension study for AVTX-803 in LAD type II
This trial is a follow-up study testing whether AVTX-803 continues to be safe and effective for people with Leukocyte Adhesion Deficiency type II (LAD II). If you already took part in an earlier AVTX-803 LAD II study, this may be the next step while researchers monitor benefits and side effects.
Rochester, MinnesotaAges 6 months–75 years - NCT07641426RecruitingPhase 1/Phase 2
CID-103 Treatment for Kidney Transplant Rejection
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05745532RecruitingEarly Phase 1
Autologous stem cell treatment to improve beta thalassemia major
This early-phase trial tests a new way to restore working blood-making cells using your own stem cells for people with transfusion-dependent beta thalassemia major. The goal is to improve safety and blood results, and possibly reduce problems from the disease.
Shenzhen, GuangdongAges 8–16 - NCT07178769Recruiting
Testing a supplement for lowering cholesterol
This trial tests a nutritional supplement with bergamot, artichoke, and other natural ingredients to see if it can safely lower cholesterol in people with moderately high LDL. It may be an option for those not currently on other cholesterol treatments.
Madrid, MadridAges 18 years+ - NCT06850805RecruitingPhase 3
Nasal spray for teens with chronic sinusitis without polyps
This study tests a new nasal spray (OPN-375) for teens aged 12–17 with chronic sinusitis but without nasal polyps. It aims to see if the spray improves symptoms like congestion and runny nose.
Gilbert, ArizonaAges 12–17 - NCT06210490RecruitingPhase 2
Antibody-drug combo with radiation for HER2+ UTUC after surgery
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06754644RecruitingPhase 3
Study of QL2107 plus chemo vs. Keytruda for advanced lung cancer
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
Jinan, ShandongAges 18–75 - NCT07627347Recruiting
Anlotinib and Bemocizumab for Early Esophageal Cancer
This study tests two drugs (anlotinib and bemocizumab) given before surgery to shrink esophageal squamous cell carcinoma (a type of throat cancer). The goal is to see if this combination helps patients have better outcomes and fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT06189495RecruitingPhase 2
Study of Genakumab for lung scarring from connective tissue disease
This study tests a new injected medication (Genakumab) for people with connective tissue disease-related lung scarring. It aims to see if it helps stabilize or improve lung function safely.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,818 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.